Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Aug 07, 2026
Tradr 2X Short SNDK Daily ETF (SNDQ) Drops -20% in 30 Days Amid Sandisk Volatility

Tradr 2X Short SNDK Daily ETF (SNDQ) Drops -20% in 30 Days Amid Sandisk Volatility

Key Takeaways

  • SNDQ declined approximately 20% over the last 30 days, while the underlying stock Sandisk (SNDK) also fell roughly 22% — an unusual outcome for a -2x inverse ETF that underscores the compounding risks of daily-reset leveraged products.
  • Over the last quarter, SNDQ has dropped approximately 64%, reflecting extreme volatility decay during one of the most turbulent periods in the memory semiconductor sector.
  • The ETF's performance was shaped primarily by Sandisk's wild price swings: an 858% first-half rally, a 47% July collapse, and a post-earnings sell-off in early August despite record quarterly results.
  • Daily reset mechanics, a 1-for-10 reverse stock split on July 21, and massive two-way daily moves in Sandisk shares combined to erode SNDQ's value even during a period when the underlying stock declined.
  • SNDQ is explicitly designed for single-day tactical trading, not multi-day or buy-and-hold strategies — a structural characteristic reinforced by the fund's recent price action.

Tradr 2X Short SNDK Daily ETF (SNDQ) Overview and Portfolio Exposure

The Tradr 2X Short SNDK Daily ETF seeks daily investment results, before fees and expenses, that correspond to two times the inverse (-200%) of the daily performance of Sandisk Corporation (SNDK) common shares. Launched on April 22, 2026, and issued by AXS Investments LLC under the Tradr ETFs family, SNDQ is a leveraged inverse single-stock ETF — a relatively new category of exchange-traded product that provides magnified short exposure to individual equities.

The fund maintains at least 80% exposure to financial instruments that deliver -2x daily leveraged returns on SNDK, primarily through swap agreements and derivatives. It holds approximately three positions and is structured as a non-diversified fund. The net expense ratio stands at 1.49%, and assets under management (AUM) were approximately $135 million as of late July 2026. Average daily volume routinely exceeds 10 million shares, reflecting active trader interest in this high-volatility instrument.

Because SNDQ resets its leverage daily, its multi-day returns can deviate substantially from a simple -2x multiple of Sandisk's cumulative return. This compounding effect is especially pronounced during periods of elevated volatility and sharp reversals — precisely the conditions that have defined Sandisk's price action in recent months. I also checked this using Tickeron’s AI Screener to see how the ETF compares to others in the leveraged products space.

Tradr 2X Short SNDK Daily ETF (SNDQ) Price Performance: Last 30 Days vs. Quarter

Over the 30-day period ending August 6, 2026, SNDQ fell approximately 20%, declining from a closing price near $34.60 to $27.80. The path was anything but linear. The fund swung between approximately $23.75 and $60.79 — a range spanning more than 150% of the starting price — reflecting daily moves of 10% to 25% in either direction on multiple occasions.

Over the broader quarter, the degradation is far steeper. From roughly $76.70 in early May to $27.80 in early August, SNDQ has lost approximately 64% of its value. This includes the impact of a 1-for-10 reverse stock split executed on July 21, which consolidated outstanding shares to maintain a viable trading price. The quarterly decline illustrates how daily-reset inverse leveraged products can experience severe NAV erosion when the reference asset experiences sustained directional moves punctuated by sharp counter-trend rallies.

Sandisk itself declined approximately 22% over the 30-day window and about 19% over the trailing three months, yet both SNDQ and SNDK moved lower together — a counterintuitive result that highlights the structural limitations of inverse leveraged ETFs in volatile, non-trending markets.

What Drove SNDQ Price in the Last 30 Days

The single dominant factor behind SNDQ's recent performance is the behavior of Sandisk Corporation. As one of 2026's most extraordinary market stories, Sandisk entered July having returned roughly 858% year-to-date, fueled by an acute global shortage of NAND flash memory — the storage chips that power AI data centers, enterprise SSDs, and consumer devices. The stock peaked at an all-time closing high of $2,335 on June 25 before embarking on a dramatic reversal.

During the 30-day period under review, several forces converged to generate extreme two-way volatility in Sandisk shares. The memory and AI infrastructure sectors underwent a broad repricing as investors reassessed the sustainability of hyperscaler capital expenditures. SK Hynix reported record quarterly results that nevertheless missed elevated bottom-line estimates, triggering a sector-wide sell-off. Chinese memory manufacturer CXMT launched a blockbuster Shanghai IPO, intensifying fears that new supply could eventually pressure NAND pricing. Meanwhile, South Korean regulators tightened rules on single-stock leveraged ETFs in mid-July, forcing deleveraging that rippled through related U.S. instruments.

In early August, Sandisk delivered fiscal fourth-quarter results that were objectively extraordinary: revenue of $8.97 billion (up 372% year-over-year), GAAP net income of $6.90 billion, and data center revenue that more than doubled sequentially. The company also announced a $14 billion share repurchase expansion. Yet the stock fell sharply because first-quarter revenue guidance, while strong, landed marginally below the most aggressive analyst forecasts — a reminder of how elevated expectations had become.

For SNDQ, the combination of Sandisk's large daily swings in both directions proved particularly destructive. The -2x daily reset means that a 5% up day in Sandisk produces a roughly 10% loss in SNDQ, and the compounded math ensures that even subsequent down days in Sandisk do not fully restore SNDQ's value. This volatility decay, compounded by the July 21 reverse split, drove SNDQ lower even as the underlying stock declined over the full period.

What Drove SNDQ Performance Over the Last Quarter

The quarterly performance of SNDQ is best understood as the product of two distinct phases in Sandisk's trajectory. From early May through late June, Sandisk continued its relentless advance, climbing from approximately $1,562 to $2,335 as AI-driven NAND demand overwhelmed constrained supply. During this phase, the -2x inverse SNDQ experienced a near-total collapse, falling from around $76.70 to below $20 — a decline of roughly 75% in under two months.

The second phase — the July-August correction — offered SNDQ a partial recovery as Sandisk shed nearly half its value. However, the daily-reset mechanics meant that SNDQ could not fully recapture the gains implied by a simple -2x calculation. The fund rallied sharply on Sandisk's worst days but gave back those gains when Sandisk bounced. Over the full quarter, the net effect was a 64% decline in SNDQ's share price.

Broader macroeconomic currents also played a role. The Federal Reserve held interest rates steady at its late-July meeting but signaled a hawkish tilt amid persistent inflation concerns tied to elevated energy prices and the ongoing conflict in the Middle East. Rising oil prices and uncertainty around future rate policy contributed to a risk-off rotation that hit richly valued technology and semiconductor names particularly hard, amplifying the volatility that SNDQ both tracks and magnifies.

SNDQ ETF Outlook: What Investors Should Watch Next

The outlook for SNDQ is inseparable from the outlook for Sandisk and the broader NAND flash memory cycle. Several factors warrant close attention in the months ahead. First, Sandisk's fiscal 2027 guidance and the trajectory of NAND pricing will be critical. Management has signed multi-year supply agreements worth over $42 billion in minimum contracted revenue, and Wall Street projects approximately 151% revenue growth for fiscal 2027 — but memory cycles have historically turned abruptly, and any sign that supply is catching up with demand would pressure Sandisk shares and, by extension, benefit SNDQ in the short term while potentially setting up renewed volatility decay.

Second, the Federal Reserve's interest rate path remains a macro wildcard. Sticky inflation and elevated energy costs could force a more restrictive monetary stance, weighing on growth stocks and potentially accelerating sector rotation out of semiconductor names. Third, Chinese competition — particularly from CXMT and the broader expansion of domestic Chinese memory production — will remain a structural overhang for the entire memory complex. Fourth, the sustainability of hyperscaler AI capital expenditure remains under scrutiny; any signal from AMZN, GOOGL, or MSFT that AI infrastructure spending is moderating would likely trigger sector-wide repricing.

Finally, investors in SNDQ must recognize that this product is engineered exclusively for short-term tactical positioning. The daily reset feature, a 1.49% expense ratio, and the mathematics of compounding mean that holding periods beyond a single trading session carry risks that are structurally different from those of conventional ETFs. Monitoring daily volume, premiums or discounts to NAV, and the pace of share creation and redemption will be essential for anyone engaging with this instrument.

AI Screener

In my research on volatile instruments like leveraged ETFs, I frequently rely on Tickeron’s AI Screener to scan for technical patterns, volatility metrics, and industry comparisons. It helps me quickly filter opportunities in fast-moving sectors such as semiconductors and thematic products, saving time compared with manual reviews. The platform supports customizable filters for signals and price patterns that align with tactical strategies.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SNDQ

Contributor

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.


Industry description

The investment seeks daily investment results, before fees and expenses, that correspond to two times the inverse (-200%) daily performance of the common shares of Sandisk Corp. Under normal market circumstances, the fund will maintain at least 80% exposure to financial instruments that provide two times inverse leveraged exposure to the daily performance of SNDK. It is non-diversified.
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Details
Category
Trading--Inverse Equity
Address
Investment Managers Series Trust II803 West Michigan StreetMilwaukee
Phone
(414) 299-2295
Web
N/A
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.